QIAGEN provides a broad range of solutions for COVID-19 testing and research, including: Syndromic and targeted testing, Antibody and Antigen testing, RNA extraction and PCR components and NGS and bioinformatics services.

 Increased access to testing for SARS-CoV-2 infection is critical to control the COVID-19 pandemic. QIAGEN’s QIAreach SARS-CoV-2 Antigen Test is a scalable, easy-to-use digital assay for the in vitro detection of the SARS-CoV-2 nucleocapsid protein antigen. It provides high test performance with results in just 2–15 minutes.

 Testing is performed with a single-use, disposal lateral flow cartridge. Test results are displayed on a portable, battery-operated eHub.

 The QIAreach SARS-CoV-2 Antigen Test is flexible and scalable. Patient samples are collected with approved nasopharyngeal swabs and transport media according to the manufacturer’s instructions. The sample is mixed with diluent buffer in a processing tube, and then transferred to the QIAreach eStick. The test will run automatically and display a result.

 QIAreach SARS-CoV-2 Antigen test results are displayed on the QIAreach eHub. The QIAreach SARS-CoV-2 Antigen Test offers 90% clinical sensitivity and 100% clinical specificity for detection of SARS-CoV-2 infection.

 For more information visit QIAGEN.com/QIAreach-Antigen-Test

View the presentation.

Our Speaker Sponsors

Questions about Registration, please email info@aohp.org or call AOHP Headquarters at 800-362-4347.